Wockhardt’s stock rocketed 9.5% in early trade on Friday, reaching ₹1,583, its highest point in nine years. The surge came after the company secured regulatory approval for Miqnaf (nafithromycin), a groundbreaking antibiotic to treat Community-Acquired Bacterial Pneumonia (CABP) in adults. The approval by the Central Drugs Standard Control Organization (CDSCO) follows a nod from its Subject Expert Committee, bolstering Wockhardt’s position as an innovator in pharmaceutical solutions. This momentum isn’t limited to Miqnaf. The company’s US FDA Fast Track-designated β-lactam enhancer, WCK 6777, also completed Phase I trials in the US, highlighting a pipeline rich with potential. Financially, Wockhardt is riding high. Q2FY25 revenue hit ₹818 crore, up 7% quarter-on-quarter, while EBITDA surged 71% to ₹139 crore. For the first half of FY25, revenue grew 10% year-on-year to ₹1,565 crore, and EBITDA more than doubled, climbing 112% to ₹239 crore.